Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$87.7MCash on Hand
14.7mo Cash Runway
Follow SPRB by emailGet an email when SPRB reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about SPRB, unsubscribe in one click. Privacy
📣 What SPRB Says Is Next
in December 2026 · “TrAnsform confirmatory study on track to initiate in December 2026: The planned TrAnsform confirmatory study is a randomized, single-blind, parallel-group, controlled, multicenter study evaluating the safety, tolerability and efficacy of intracerebroventricular (“ICV”)-administered TA-ERT compared to standard of care in children 1 to 5 years of age with severe (non-attenuated) MPS IIIB.”
Company press release, Nov 9, 2026 · SEC filing
in December 2026 · “BLA submission for TA-ERT for the treatment of MPS IIIB remains on track for December 2026: Spruce anticipates submitting a BLA in December 2026 seeking accelerated approval of TA-ERT for the treatment of mucopolysaccharidosis type IIIB (“MPS IIIB”), or Sanfilippo Syndrome Type B, based on reduction of cerebrospinal fluid heparan sulfate non-reducing end (“CSF HS-NRE”) as a reasonably likely surrogate endpoint of clinical benefit.”
Company press release, Nov 9, 2026 · SEC filing
in December · ““Our pre-BLA meetings with the FDA in the second quarter provided alignment on the content and format of the BLA, and we remain on track to complete our second Process Performance Qualification (“PPQ”) batch and initiate our TrAnsform confirmatory study as planned in December.” “We have also taken deliberate steps to strengthen our balance sheet and sharpen our strategic focus,” continued Dr. Szwarcberg.”
Company press release, Nov 9, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 9, 2026 ·
Restructuring Reported Q3 2026 results and updates: BLA for TA-ERT for MPS IIIB on track for December 2026. Amended Avenue loan raises Tranche 2 to $15.0 million. CRHX-101 separated into Adrenyx Biosciences, with a planned distribution to shareholders in the first half of 2027. Form 8-K · SEC filing · Press release
Nov 9, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Aug 12, 2026 ·
Earnings Reported Q2 2026 cash of $96.3 million and a net loss of $16.2 million, or $(6.68) per share. Cash is expected to fund operations into the second half of 2027. Plans to submit a BLA for TA-ERT for MPS IIIB in Q4 2026 and begin the TrAnsform confirmatory study in Q4 2026. Form 8-K · SEC filing · Press release
Aug 12, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Jul 2019 · Phase 2 · Results Expected · Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia Registry primary completion date, not a results date
Mar 2019 · Phase 2 · Results Expected · Study of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
SPRB holds $87.7M in cash and short-term investments (as of Sep 30, 2026) and burns about $17.9M/quarter from operations,
an estimated runway of 14.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:78 · High
Cash runway 15 months +18
ATM program on file since Apr 2026 +15
Shelf registration (S-3, Oct 2025) +10
Going-concern doubt in the latest 10-Q +15Accordingly, there is substantial doubt about the Company’s ability to continue as a going concern for at least 12 months following the issuance date of these condensed consolidated financial statements.10-Q, Nov 2026
Share count 2,874,013 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full SPRB picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SPRB and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.